Core Viewpoint - The company, Yimai Sunshine (02522), has seen its stock price increase by over 4%, currently trading at 15.46 HKD, with a transaction volume of 51.26 million HKD, following the announcement of a significant investment in Shanghai Yinghe Medical Technology Co., Ltd. [1] Group 1: Investment and Strategic Moves - Yimai Sunshine has entered into a capital increase subscription agreement with Shanghai Yinghe Medical Technology Co., Ltd., investing nearly 100 million RMB to subscribe to the new registered capital of Yinghe Medical [1] - This investment will enhance the company's total equity stake in Yinghe Medical, aligning with its strategy in the medical imaging AI sector, which integrates medical imaging data, AI foundational models, and imaging center scenarios [1] Group 2: Achievements and Future Prospects - By the end of October 2025, a medical imaging database co-built by the three parties successfully achieved its first commercial conversion contract in a data sandbox environment, providing a large model training service valued at tens of millions of RMB [1] - This achievement signifies a substantial breakthrough for the company in the marketization and value realization of medical imaging data assets, further deepening its strategic layout in the data business sector and enhancing its comprehensive competitiveness in the medical imaging AI field [1]

Core Viewpoint - The company has entered into a capital increase agreement with Shanghai Yinghe Medical Technology Co., Ltd., investing nearly 100 million RMB to enhance its stake, reflecting a strategic move to strengthen its position in the rapidly growing medical imaging AI sector [1][2]. Group 1 - The investment aligns with the company's strategy of integrating medical imaging data, AI models, and imaging center scenarios, enhancing its long-term development in the medical imaging field [2]. - The partnership with Yinghe Medical will activate a "twin incubation" mechanism, leveraging the company's quality data resources and Yinghe's AI technology to create a beneficial interaction between information, data, and AI capabilities [2]. - The investment is expected to improve the company's competitive position in the fast-growing imaging AI market, enabling sustained business growth [2][3]. Group 2 - The investment will enhance the company's layout in the medical imaging industry chain, improving the precision and efficiency of imaging diagnostic services [3]. - By utilizing Yinghe's technological advantages, the company aims to transition towards a data-driven service model, thereby increasing its core competitiveness in the industry [2][3]. - The establishment of a "data + algorithm + scenario" closed-loop system will solidify the company's leadership position in China's medical imaging AI sector [3].

Core Insights - The company Yimai Sunshine (02522) announced the launch of the world's first AI-assisted diagnostic product, AIR, developed by its affiliated AI company, Shanghai Yinghe Medical Technology Co., Ltd. This product marks a significant advancement in medical imaging AI, transitioning from the "single disease small model" era to the "foundation model-driven" era, showcasing capabilities for comprehensive diagnosis across multiple organs and diseases [1][2] Group 1 - The AIR product focuses on chest CT scans, enabling simultaneous detection and diagnosis of all common diseases in the lungs, pleura, and mediastinum with a single scan [1] - AIR is based on the world's first cross-modal, full-process medical imaging foundation model, "Yinghe Mijia," which enhances diagnostic efficiency, precision, and seamless integration [1][2] - The launch of AIR signifies a shift from "single-point breakthroughs" to "systematic empowerment" in medical imaging AI, transforming the industry from "single disease detection" to "multi-disease collaborative analysis" [2] Group 2 - AIR serves as the first commercial outcome of the Yinghe Medical foundation model ecosystem, connecting top hospitals with grassroots medical institutions to create a positive feedback loop for data-driven model iteration and scene implementation [2] - This model is expected to significantly shorten AI product development cycles, reduce costs, and promote standardized screening, intelligent diagnosis, and inclusive services across the healthcare industry [2] - The technological innovation of "one scan, multiple disease simultaneous diagnosis" is anticipated to enhance the competitiveness and added value of the company's imaging center services [2]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不就因本公告全部或任何部分內容所產生或因依 賴該等內容而引致的任何損失承擔任何責任。 Jiangxi Rimag Group Co., Ltd. 江西一脈陽光集團股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：2522） 自願公告 影禾醫脈發佈全球首個基座大模型驅動的AI輔助診斷產品 本公告由江西一脈陽光集團股份有限公司（「本公司」，連同其附屬公司統稱為「本 集團」）董事（「董事」）會（「董事會」）自願作出。 董事會欣然宣佈，2025年10月16日，由本集團參股孵化的人工智能公司上海影 禾醫脈智能科技有限公司（「影禾醫脈」），正式發佈全球首個基於醫學影像基座大 模型「影禾覓芽®」研發的AIR（路徑級AI輔助診斷產品）——胸部CT平掃輔助診斷 AIR（「AIR產品」）。AIR產品標誌着醫學影像AI正式從「單病種小模型」的1.0時 代，邁入「基座大模型驅動」的2.0時代，具備全病灶、全病種、多器官協同診斷 能力，是醫學影像智能診斷領域的一項里程碑式突破。 AIR產品不僅 ...

Core Viewpoint - The company, Yipai Yangguang (02522), has announced a share placement to raise approximately HKD 562 million, with a focus on expanding its capabilities in data and artificial intelligence within the medical imaging sector [1] Group 1: Share Placement Details - Yipai Yangguang plans to place 35 million shares at a discount of about 12.53%, aiming to raise net proceeds of approximately HKD 562 million [1] - Approximately 40% of the net proceeds will be allocated to the development of data and AI capabilities, specifically in medical imaging data mining, annotation, and cleaning [1] - About 30% of the net proceeds will be used for expanding the company's medical imaging center business through self-investment or acquisitions, targeting both domestic and overseas markets, including Hong Kong and Singapore [1] Group 2: Financial Performance - For the six months ending June 30, 2025, the company reported revenue of RMB 467 million, a year-on-year increase of 12.89% [1] - Gross profit was reported at RMB 137 million, with a significant increase in net profit attributable to shareholders of RMB 16.44 million, reflecting a year-on-year growth of 328.65% [1] - The company anticipates that its newly established imaging center projects will gradually commence operations in the second half of 2025, coinciding with the expected recovery of national medical equipment update demands by the end of 2024 [1]

Core Viewpoint - The company, Yipai Yangguang (02522), has announced a share placement to raise approximately HKD 562 million, with a discount of about 12.53%, to fund its development in data and artificial intelligence, as well as to expand its medical imaging business [1] Group 1: Share Placement and Fund Allocation - Yipai Yangguang plans to place 35 million shares at a discount of approximately 12.53%, aiming to raise net proceeds of about HKD 562 million [1] - Approximately 40% of the net proceeds will be allocated to the development of data and AI capabilities, focusing on medical imaging data mining, annotation, and cleaning services [1] - About 30% of the net proceeds will be used for expanding the company's medical imaging center business and enabling solution services through self-investment or acquisitions, targeting both domestic and overseas markets, including Hong Kong and Singapore [1] Group 2: Financial Performance - For the six months ending June 30, 2025, the company reported revenue of RMB 467 million, representing a year-on-year increase of 12.89% [1] - Gross profit was reported at RMB 137 million, with a significant increase in net profit attributable to shareholders of RMB 16.44 million, up 328.65% year-on-year [1] - The company anticipates that its newly established imaging center projects will gradually commence operations in the second half of 2025, benefiting from the ongoing release of national medical infrastructure policies [1]

Core Viewpoint - The company, Yipai Yangguang (02522.HK), has announced a placement agreement to issue 35 million shares at a price of HKD 16.76 per share, which represents approximately 13.55% of the existing H-shares and 9.58% of the total issued shares as of the announcement date [1][2]. Group 1 - The placement is expected to raise approximately HKD 586.6 million in total proceeds, with a net amount of about HKD 562.1 million after expenses [2]. - The net proceeds from the placement will be allocated as follows: approximately 40% for the development of data and artificial intelligence in medical imaging, 30% for expanding the medical imaging center business through investments or acquisitions, 20% for establishing an incubation fund for quality healthcare enterprises, and 10% for general working capital [2]. Group 2 - The company aims to deepen its capabilities in data services related to medical imaging by collaborating with leading enterprises in AI and healthcare, as well as major hospitals in China [2]. - The strategic focus includes establishing a data space and creating a convertible imaging center, while also building an investment portfolio in high-quality enterprises within the medical field [2].

Group 1 - The China Securities Regulatory Commission (CSRC) has issued supplementary material requirements for 17 companies, including Deshi Biotech, regarding their overseas listing applications [1] - Deshi Biotech submitted its listing application to the Hong Kong Stock Exchange on June 29, 2025, with Huatai International as the sole sponsor [1] - The CSRC requires Deshi Biotech to clarify its business scope and whether it involves any foreign investment restrictions, particularly in areas like human stem cells and gene diagnosis and treatment [1][2] Group 2 - Deshi Biotech's iMedImage is recognized as the world's largest general medical imaging base model and has achieved commercialization [2] - The iMedImage model supports 19 types of medical imaging modalities and covers over 90% of clinical medical imaging scenarios, including reproductive health and hematological malignancies [2] - The solutions provided by iMedImage significantly reduce R&D costs and time to market, addressing uneven distribution of medical resources and improving diagnostic efficiency [2]

Group 1 - The China Securities Regulatory Commission (CSRC) has issued supplementary material requirements for 17 companies, including Deshi Biotech, regarding their overseas listing applications [1][2] - Deshi Biotech submitted its listing application to the Hong Kong Stock Exchange on June 29, 2025, with Huatai International as the sole sponsor [1] - The CSRC has requested Deshi Biotech to clarify its business scope and whether it involves any foreign investment restrictions, particularly in areas like human stem cells and gene diagnosis and treatment [1][2] Group 2 - Deshi Biotech's proprietary iMedImageTM is recognized as the world's largest general medical imaging base model and has been commercialized successfully [2] - The iMedImageTM model supports 19 types of medical imaging modalities and covers over 90% of clinical medical imaging scenarios, enhancing diagnostic efficiency and addressing uneven distribution of medical resources [2] - The company focuses on AI solutions for medical imaging, which significantly reduce R&D costs and time to market, providing scalable innovative pathways for smart healthcare [2]

Core Viewpoint - Hangzhou Deshi Bio is leading the AI medical diagnosis sector with its self-developed iMedImage universal medical imaging model, aiming for an IPO in Hong Kong with a valuation of 2.56 billion yuan after the latest funding round [1] Group 1: iMedImage Model and Market Potential - iMedImage is designed to address the challenges in the medical imaging market, which is projected to reach 180 billion yuan in China by 2030, with AI in medical imaging being one of the fastest-growing segments globally [1][5] - The model significantly reduces development time from the industry average of 3-5 years to under 60 days and cuts AI R&D costs by over 90% [1][3] - The model's architecture allows for the creation of specialized models with only 200 image samples, drastically lowering data requirements compared to traditional methods [3] Group 2: Competitive Advantages and Innovations - iMedImage provides a comprehensive solution that includes six AI analysis systems, three AI medical devices, and various model services, positioning the company as a leader in the market with a 30.6% share in 2024 [5][6] - The platform supports cross-modal compatibility and can handle 19 types of medical imaging modalities, covering over 90% of clinical scenarios [6] - The accuracy of diagnostic systems using iMedImage has improved from an average of 50% to 99.45%, and the time to generate clinical reports has been reduced from nearly 30 days to just 4 days [6] Group 3: Financial Performance and Growth - The company reported revenues of 52.84 million yuan in 2023 and 70.35 million yuan in 2024, with a 33.1% year-on-year growth in cloud service revenue [7] - The gross margin for products has consistently exceeded 65%, indicating strong market acceptance and technological premium [7] - The net loss for 2024 is projected to be approximately 43.38 million yuan, a reduction of nearly 23% from the previous year, reflecting robust growth momentum [7] Group 4: Future Development and Strategic Goals - The company plans to use the funds raised for the development and commercialization of its core product, AI AutoVision, and further iterations of the iMedImage model [8] - The strategic goal is to transition from an "AI tool provider" to a "full-modal medical AI infrastructure architect," aiming to share AI benefits across all device manufacturers and clinical hospitals [8]